Cipla Patent-Cliff Exposure & CMS Drug Spending Portfolio
Cipla (Warren, NJ): 8 reconciled FDA prescription therapies, $92.4M 2024 CMS Part D & Medicaid spend, and $22,031 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Warren, NJ |
| Reconciled FDA Portfolio Therapies | 8 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $92.4M |
| 2024 Medicare Part D Spend | $76.3M |
| 2024 Medicaid Spend | $16.1M |
| California HCAI SB 17 Filings | Specialty launch notice ($22,031 intro WAC) |